title: Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.
abstract: BACKGROUND
  The prognostic value of epidermal growth factor receptor (EGFR) mutations in resected non-small cell lung cancer (NSCLC) remains controversial. We performed a systematic review with meta-analysis to assess its role.
  
  
  METHODS
  Studies were identified via an electronic search on PubMed, Embase and Cochrane Library databases. Pooled hazard ratio (HR) for disease-free survival (DFS) and overall survival (OS) were calculated for meta-analysis.
  
  
  RESULTS
  There were 16 evaluated studies (n  =  3337) in the meta-analysis. The combined HR evaluating EGFR mutations on disease free survival was 0.96 (95% CI [0.79-1.16] P  =  0.65). The combined HR evaluating EGFR mutations on overall survival was 0.86 (95% CI [0.72-1.04] P  = 0.12). The subgroup analysis based on univariate and multivariate analyses in DFS and OS showed no statistically significant difference. There was also no statistically significant difference in DFS and OS of stage I NSCLC patients.
  
  
  CONCLUSIONS
  The systematic review with meta-analysis showed that EGFR mutations were not a prognostic factor in patients with surgically resected non-small cell lung cancer. Well designed prospective study is needed to confirm the result.
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Zhixuan
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Cai
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Changchuan
authors.initials: C
authors.lastname: Pan
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Long
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Chengya
authors.initials: C
authors.lastname: Zhou
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, PR China.
authors.forename: Xude
authors.initials: X
authors.lastname: Yin
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D066246:ErbB Receptors / Q000235:genetics*; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D009154:Mutation; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D066246:ErbB Receptors